TUCSON, Ariz., Sept. 24 /PRNewswire/ -- Ventana Medical Systems, Inc.
(Nasdaq: VMSI) today announced that its Board of Directors has authorized a
stock repurchase program whereby up to 750,000 shares of its Common Stock may
be purchased in the open market from time to time. The Company intends to use
the repurchased stock for replenishment of shares issued pursuant to employee
option plans.
Ventana develops, manufactures and markets proprietary instrument/reagent
systems that automate immunohistochemistry ("IHC") and in situ hybridization
("ISH") tests for the analysis of cells and tissues on microscope slides.
These tests are important tools used in the diagnosis and treatment of cancer.
SOURCE Ventana Medical Systems, Inc.
 back to top
CONTACT:
Henry T. Pietraszek, President and Chief
Executive Officer of Ventana Medical Systems, 520-887-2155; or
General Inquiries, Bill Murphy, Analysts, Kathy Brunson, or Media
Inquiries, Darcy Bretz, all of The Financial Relations Board,
312-266-7800
NOTE TO EDITORS: For more information on Ventana Medical Systems,
Inc. via facsimile at no additional cost, simply dial
1-800-PRO-INFO and enter the company code 273.
|
